Cargando…
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone r...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363858/ https://www.ncbi.nlm.nih.gov/pubmed/11308265 http://dx.doi.org/10.1054/bjoc.2001.1727 |
_version_ | 1782153809356652544 |
---|---|
author | Jagdev, S P Coleman, R E Shipman, C M Rostami-H, A Croucher, P I |
author_facet | Jagdev, S P Coleman, R E Shipman, C M Rostami-H, A Croucher, P I |
author_sort | Jagdev, S P |
collection | PubMed |
description | Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4–5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro. © 2001 Cancer Research Campaign http://www.bjcancer.com |
format | Text |
id | pubmed-2363858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23638582009-09-10 The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel Jagdev, S P Coleman, R E Shipman, C M Rostami-H, A Croucher, P I Br J Cancer Regular Article Bisphosphonates are well established in the management of breast-cancer-induced bone disease. Recent studies have suggested that these compounds are effective in preventing the development of bone metastases. However, it is unclear whether this reflects an indirect effect via an inhibition of bone resorption or a direct anti-tumour effect. The breast cancer cell lines, MCF-7 and MDA-MB-231 cells were treated with increasing concentrations of the bisphosphonate, zoledronic acid, for varying time periods, in the presence or absence of paclitaxel. The effects of zoledronic acid were determined by assessing cell number and rate of apoptosis by evaluating changes in nuclear morphology and using a fluorescence nick translation assay. Zoledronic acid caused a dose- and time-dependent decrease in cell number (P< 0.001) and a concomitant increase in tumour cell apoptosis (P< 0.005). Short-term exposure to zoledronic acid was sufficient to cause a significant reduction in cell number and increase in apoptosis (P< 0.05). These effects could be prevented by incubation with geranyl geraniol, suggesting that zoledronic acid-induced apoptosis is mediated by inhibiting the mevalonate pathway. Treatment with zoledronic acid and clinically achievable concentrations of paclitaxel resulted in a 4–5-fold increase in tumour cell apoptosis (P< 0.02). Isobologram analysis revealed synergistic effects on tumour cell number and apoptosis when zoledronic acid and paclitaxel were combined. Short-term treatment with zoledronic acid, which closely resembles the clinical setting, has a clear anti-tumour effect on breast cancer cells. Importantly, the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-tumour effects of zoledronic acid. These data suggest that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-04 /pmc/articles/PMC2363858/ /pubmed/11308265 http://dx.doi.org/10.1054/bjoc.2001.1727 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Jagdev, S P Coleman, R E Shipman, C M Rostami-H, A Croucher, P I The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
title | The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
title_full | The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
title_fullStr | The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
title_full_unstemmed | The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
title_short | The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
title_sort | bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363858/ https://www.ncbi.nlm.nih.gov/pubmed/11308265 http://dx.doi.org/10.1054/bjoc.2001.1727 |
work_keys_str_mv | AT jagdevsp thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT colemanre thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT shipmancm thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT rostamiha thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT croucherpi thebisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT jagdevsp bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT colemanre bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT shipmancm bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT rostamiha bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel AT croucherpi bisphosphonatezoledronicacidinducesapoptosisofbreastcancercellsevidenceforsynergywithpaclitaxel |